BIA
NKTR icon

Bell Investment Advisors’s Nektar Therapeutics NKTR Stock Holding History

Bell Investment Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$3K Buy
15
+8
+114% +$1.74K ﹤0.01% 1007
2021
Q3 		$2K Buy
+7
New +$1.68K ﹤0.01% 1113

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bell Investment Advisors's NKTR Position: Q4 2021 in Review

Bell Investment Advisors increased its Nektar Therapeutics (NKTR) stake by 114% in Q4 2021, buying an estimated $1.74K and bringing the position to 15 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1007.

Bell Investment Advisors first reported a position in NKTR in Q3 2021 and has held it in 2 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

  • Bell Investment Advisors held 15 shares of Nektar Therapeutics worth $3K as of Q4 2021.
  • Bell Investment Advisors bought 8 Nektar Therapeutics shares in Q4 2021, an estimated $1.74K.
  • Nektar Therapeutics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q4 2021, its #1007 holding.
  • Bell Investment Advisors first reported a position in Nektar Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Bell Investment Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.